A
Amarnath Sharma
Researcher at Pfizer
Publications - 24
Citations - 1034
Amarnath Sharma is an academic researcher from Pfizer. The author has contributed to research in topics: Pharmacokinetics & Cmax. The author has an hindex of 14, co-authored 22 publications receiving 987 citations.
Papers
More filters
Journal ArticleDOI
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Paul Haluska,Heather Shaw,Gretchen N. Batzel,Donghua Yin,Julian R. Molina,L Rhoda Molife,Timothy A. Yap,Roberts Maria Luisa,Amarnath Sharma,Antonio Gualberto,Alex A. Adjei,Johann S. de Bono +11 more
TL;DR: CP-751,871 has a favorable safety profile and was well tolerated when given in continuous cycles, and at the maximal feasible dose of 20 mg/kg, there was a moderate accumulation in plasma exposure, and most of the treated patients experienced stability of disease.
Journal ArticleDOI
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
Martha Q. Lacy,Melissa Alsina,Rafael Fonseca,M. Luisa Paccagnella,Carrie Lynn Melvin,Donghua Yin,Amarnath Sharma,M. Enriquez Sarano,Michael Pollak,Sundar Jagannath,Paul G. Richardson,Antonio Gualberto +11 more
TL;DR: Data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma.
Journal ArticleDOI
Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic–genotypic correlates
TL;DR: The distribution of the SNP C3435T in exon 26 in the Chinese and Malay population was found to be similar to the Caucasians whereas the Indians were different, and the Asian population differed significantly from the African and Caucasian population in the distribution of this SNP.
Journal ArticleDOI
Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen
Ping Liu,Hameed Allaudeen,Richa Chandra,Kem Phillips,Arvid Jungnik,Jeanne D. Breen,Amarnath Sharma +6 more
TL;DR: The single-dose regimen provided total azithromycin exposures in serum and WBC similar to those of the 3-day regimen, as evidenced by the similar AUC0-120 and trough azithrolycin concentrations in serum or WBC (mononuclear leukocytes [MNL].
Journal ArticleDOI
Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects
Ping Liu,Grover Foster,Kuan Gandelman,Robert R. LaBadie,Mark J. Allison,Maria J. Gutierrez,Amarnath Sharma +6 more
TL;DR: It is interesting that one subject in each study exhibited the opposite effect of ritonavir on voriconazole exposure, probably due to lack of CYP2C19, and coadministration with 100 mg BID ritonvir should be avoided, unless an assessment of the benefit/risk to the patient justifies the use.